Let’s Get Started
We have several resources to help you access your medicine. Answer no more than 6 simple questions to find out which one might be right for you.
A
A
A
Patient
Education > En
Español > Call (877) 436-3683
- ACTEMRA® (tocilizumab)
- ALECENSA® (alectinib)
- AVASTIN® (bevacizumab)
- COTELLIC® (cobimetinib)
- ENSPRYNG™ (satralizumab-mwge)
- ERIVEDGE® (vismodegib)
- ESBRIET® (pirfenidone)
- Evrysdi® (risdiplam)
- GAVRETO® (pralsetinib)
- GAZYVA® (obinutuzumab)
- HEMLIBRA® (emicizumab-kxwh)
- HERCEPTIN® (trastuzumab)
- HERCEPTIN HYLECTA™ (trastuzumab and hyaluronidase-oysk)
- KADCYLA® (ado-trastuzumab emtansine)
- LUCENTIS® (ranibizumab injection)
- OCREVUS® (ocrelizumab)
- PERJETA® (pertuzumab)
- PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
- POLIVY® (polatuzumab vedotin-piiq)
- PULMOZYME® (dornase alfa) Inhalation Solution
- RITUXAN® (rituximab)
- RITUXAN HYCELA® (rituximab/hyaluronidase human)
- ROZLYTREK® (entrectinib)
- SUSVIMO™ (ranibizumab injection)
- TECENTRIQ® (atezolizumab)
- VENCLEXTA® (venetoclax tablets)
- XELODA® (capecitabine)
- XOLAIR® (omalizumab) for subcutaneous use
- ZELBORAF® (vemurafenib)
Please select a treatment to continue
- ACTEMRA® (tocilizumab)
- ALECENSA® (alectinib)
- AVASTIN® (bevacizumab)
- COTELLIC® (cobimetinib)
- ENSPRYNG™ (satralizumab-mwge)
- ERIVEDGE® (vismodegib)
- ESBRIET® (pirfenidone)
- Evrysdi® (risdiplam)
- GAVRETO® (pralsetinib)
- GAZYVA® (obinutuzumab)
- HEMLIBRA® (emicizumab-kxwh)
- HERCEPTIN® (trastuzumab)
- HERCEPTIN HYLECTA™ (trastuzumab and hyaluronidase-oysk)
- KADCYLA® (ado-trastuzumab emtansine)
- LUCENTIS® (ranibizumab injection)
- OCREVUS® (ocrelizumab)
- PERJETA® (pertuzumab)
- PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
- POLIVY® (polatuzumab vedotin-piiq)
- PULMOZYME® (dornase alfa) Inhalation Solution
- RITUXAN® (rituximab)
- RITUXAN HYCELA® (rituximab/hyaluronidase human)
- ROZLYTREK® (entrectinib)
- SUSVIMO™ (ranibizumab injection)
- TECENTRIQ® (atezolizumab)
- VENCLEXTA® (venetoclax tablets)
- XELODA® (capecitabine)
- XOLAIR® (omalizumab) for subcutaneous use
- ZELBORAF® (vemurafenib)
Or Select
- ONCOLOGY
- OPHTHALMOLOGY
- RHEUMATOLOGY
Please select a treatment to continue
Select a disease state for Rituxan® (rituximab)